echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Qilu will win over $2 billion star drug, sprint for the first domestically produced

    Qilu will win over $2 billion star drug, sprint for the first domestically produced

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Qilu Pharmaceutical has entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.


    Source: official website of the State Drug Administration

    Apemilast (apmilast/apmilast) is a new oral, small molecule phosphodiesterase 4 (PDE-4) inhibitor developed by New Base (acquired by Amgen), which is dose-dependent Sexually inhibits the release of tumor necrosis factor (TNF)-α from human synovial cells


    In addition to apremilast, the PDE-4 inhibitors currently on the market worldwide also include cliborrol, doxofylline, roflumilast, etc.


    Production status of Apster tablets

    Source: Mi Nei Net Consistency Evaluation Database

    Amgen’s Apster tablets were approved for import in August 2021.


    Qilu approved products since 2021

    Source: Meinenet MED2.


    According to data from Minai.


    Sales of 3 first generic drugs in Chinese public medical institutions and physical pharmacies in cities in China (unit: 10,000 yuan)

    Source: Mi Nei Net Database

    The 3 first generic drugs are rasagiline mesylate, metformin vildagliptin tablets and trifluridine tepipyrimine tablets.


    Source: Mi Nei.


    Source: Mi Nei.
    com database, official website of the State Drug Administration, etc.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.